The Keg Royalties Income Fund (TSX:KEG.UN)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	19.02	8.42	25.16	5.3	-5.37	22.26
Other Amortization	0.02	0.02	0.02	0.02	0.02	0.01
Other Operating Activities	9.03	18.62	2.58	21.81	23.65	-6.62
Change in Accounts Receivable	-0.15	0.6	-0.97	-0.56	-1.61	1.93
Change in Accounts Payable	0.02	-0.01	0.06	0.06	0.05	-0.13
Change in Other Net Operating Assets	-0	-	0.03	-0.01	-0.02	-0.02
Operating Cash Flow	27.94	27.65	26.86	26.62	16.71	17.44
Operating Cash Flow Growth	-0.06%	2.92%	0.90%	59.30%	-4.16%	-28.46%
Common Dividends Paid	-13.34	-13.8	-12.89	-12.89	-8.16	-7.31
Other Financing Activities	-14.19	-14.31	-14.74	-12.82	-9.19	-9.19
Financing Cash Flow	-27.54	-28.11	-27.63	-25.71	-17.35	-16.49
Net Cash Flow	0.4	-0.46	-0.76	0.92	-0.64	0.95
Cash Interest Paid	14.19	14.31	14.7	12.82	9.15	9.19
Cash Income Tax Paid	-	0.65	0.71	-0.88	-0.27	2.09
Levered Free Cash Flow	-126.26	10.9	11.01	11.92	6.87	6.67
Unlevered Free Cash Flow	-117.38	19.72	20.02	20.34	12.95	12.05
Change in Net Working Capital	138.07	0.71	0.97	-1.03	0.18	-0.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.